Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on Central Nervous System disorders and other rare disorders. Co.'s product development pipeline are: SLS-002, a intranasal racemic ketamine with two investigational new drug applications, for the treatment of acute suicidal ideation and behavior in Major Depressive Disorder and in Post-Traumatic Stress Disorder; and SLS-005, a IV Trehalose, a protein stabilizer that crosses the blood-brain-barrier, activates autophagy and lysosomal biogenesis. Additionally, Co. is developing several preclinical programs including: SLS-004 and SLS-007 for the potential treatment of Parkinson's Disease. The SEEL stock yearly return is shown above.
The yearly return on the SEEL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SEEL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|